Reviewing Kite Pharma (KITE) & Its Competitors
Kite Pharma (NASDAQ: KITE) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Kite Pharma to related companies based on the strength of its earnings, valuation, dividends, institutional ownership, profitability, risk and analyst recommendations.
Valuation & Earnings
This table compares Kite Pharma and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kite Pharma Competitors||$284.49 million||$34.10 million||73.89|
This table compares Kite Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kite Pharma Competitors||-5,310.39%||-218.43%||-39.49%|
This is a summary of current ratings and target prices for Kite Pharma and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kite Pharma Competitors||874||3235||11724||233||2.70|
Kite Pharma presently has a consensus price target of $93.20, suggesting a potential downside of 48.16%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 48.26%. Given Kite Pharma’s peers stronger consensus rating and higher possible upside, analysts clearly believe Kite Pharma has less favorable growth aspects than its peers.
Institutional and Insider Ownership
87.7% of Kite Pharma shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 14.0% of Kite Pharma shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Kite Pharma peers beat Kite Pharma on 7 of the 10 factors compared.
Kite Pharma Company Profile
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).
Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.